Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study

Inclusion Criteria: * 18-64 years of age at date of first vaccination * Good health as determined by medical history and physical inspection * Females of child-bearing potential must have a negative pregnancy test prior to first and second vaccination in the country of origin; females of child-bearing potential must agree not to become pregnant throughout the duration of study * Subjects must have planned travel to DC, within 3 hours traveling distance of approved study site(s), for a minimum duration of stay of 7 days (no maximum stay is specified for inclusion). * Subject must be able to communicate in English Exclusion Criteria: * Abnormalities as determined by the Investigator/clinician during physical inspection; * Participated in research involving investigational product within 30 days before planned date of first vaccination; * Ever received LT, ETEC, or cholera vaccine; * History of diarrhea while traveling in a developing country within the last year; * Women who are pregnant or breastfeeding; * Clinically significant underlying enteric, pulmonary, cardiac, liver or renal disease; * History of Irritable Bowel Syndrome; * Seizure disorder within the last year; * Current use of immunosuppressive therapy (excluding inhaled steroids) or immunodeficiency; * Known or suspected alcohol abuse or illicit drug use within the last year; * Medical history of HIV, HBV, or HCV; * An employee of a study site; * Known allergies to any component of the vaccine, including adhesives; * Planned use of antibiotics with known activity against gram negative facultative anaerobes; * Planned use of antacids, antidiarrheals, loperamide, bismuth subsalicylate, diphenoxylate or similar from two weeks prior to randomization through the surveillance phase of the study; * An employee of Intercell (global) or an immediate family member.